Earnings Call Summary | YS Biopharma(YS.US) Q3 2024 Earnings Conference

The following is a summary of the YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript:Financial Performance:YS Biopharma reported a total revenue of RMB 438.1 million for the first nine month

Futu NewsApr 19 21:16 · Conference Call

YS Biopharma Co (YS.US): The 2024 Q3 financial report achieved revenue of US$238.15 million, with an expected value of US$22.84 million; earnings per share of -0.12 USD, with an expected value of -0.07 USD.

YS Biopharma Co (YS.US): The 2024 Q3 financial report achieved revenue of US$238.15 million, with an expected value of US$22.84 million; earnings per share of -0.12 USD, with an expected value of -0.07 USD.

Zhitong FinanceApr 19 19:21

YS Biopharma Co 9M 2024 EPS Loss Of RMB (1.04) Versus RMB (2.71) YoY

YS Biopharma Co 9M 2024 EPS Loss Of RMB (1.04) Versus RMB (2.71) YoY

BenzingaApr 19 19:13

YS Biopharma Co 9M 2024 Sales Of $61.9M

YS Biopharma Co 9M 2024 Sales Of $61.9M

BenzingaApr 19 19:12

Press Release: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

Dr. David Shao continued, "At the corporate level, since late 2023 we have embarked on a comprehensive series of initiatives aimed at fortifying our foundation for future growth.

Dow JonesApr 19 19:00

YS Biopharma Granted Phase I Clinical Trial License Of Therapeutic Chronic Hepatitis B Virus Vaccine

YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines

BenzingaApr 18 20:11